Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v5-EN
Language English English
Date Updated 2021-01-21 2021-01-20
Drug Identification Number 02492989 02492989
Brand name NUCALA NUCALA
Common or Proper name Mepolizumab Injection Mepolizumab Injection
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients MEPOLIZUMAB MEPOLIZUMAB
Strength(s) 100MG 100MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size PRE-FILLED AUTOINJECTOR x1 / AUTOINJECTEUR PRÉ-REMPLI x1 PRE-FILLED AUTOINJECTOR x1 / AUTOINJECTEUR PRÉ-REMPLI x1
ATC code R03DX R03DX
ATC description OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-12-18 2020-12-18
Estimated end date 2021-02-01 2021-02-01
Actual end date 2021-01-20 2021-01-20
Shortage status Resolved Actual shortage
Company comments
Health Canada comments